Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes

Mantovani, Alessandro; Altomari, Anna; Lunardi, Gianluigi; Bonapace, Stefano; Lippi, Giuseppe; Bonnet, Fabrice; Targher, Giovanni

doi:10.1016/j.diabet.2019.05.008

Cited by 9 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experimentally, it has been shown that these pro-inflammatory and pro-oxidant factors may activate sphingomyelinase and other enzymes directly implicated in the production of ceramide species [3,24,25]. On the other hand, it is known that ceramides play important roles in the regulation of inflammatory responses [26][27][28]. Emerging evidence is also suggesting that sphingolipids, including certain ceramides, may play a role in the pathogenesis and J o u r n a l P r e -p r o o f 13 progression of genetic and non-genetic forms of CKD [24,29].…”

Section: Discussionmentioning

confidence: 99%

Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease

Mantovani

Lunardi

Bonapace

et al. 2021

Diabetes & Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease

Mantovani

Lunardi

Bonapace

et al. 2021

Diabetes & Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, it is known that S-SMase activity (the enzyme which catalyzes the cleavage of sphingomyelinase to ceramides) is mediated by inflammation [ 32 ]. In particular, multiple experimental and clinical findings have suggested an association between ceramides and C reactive protein [ 4 , 33 , 34 ]. Specifically, ceramides were previously found to be significantly correlated with C-reactive protein in the SPUM-ACS population, in agreement with our findings [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Ceramides and Cardiovascular Risk Factors, Inflammatory Parameters and Left Ventricular Function in AMI Patients

et al. 2022

View full text Add to dashboard Cite

Ceramides, biologically active lipids correlated to oxidative stress and inflammation, have been associated with adverse outcomes in acute myocardial infarction (AMI). The purpose of this study was to assess the association between ceramides/ratios included in the CERT1 score and increased cardiovascular (CV) risk, inflammatory and left ventricular function parameters in AMI. Methods: high performance liquid chromatography-tandem mass spectrometry was used to identify Cer(d18:1/16:0), Cer(d18:1/18:0), and Cer(d18:1/24:1) levels and their ratios to Cer(d18:1/24:0), in 123 AMI patients (FTGM coronary unit, Massa, Italy). Results: Cer(d18:1/16:0): higher in female patients (<0.05), in patients with dyslipidemia (<0.05), and it directly and significantly correlated with aging, brain natriuretic peptide-BNP, erythrocyte sedimentation rate-ESR and fibrinogen. Cer(d18:1/18:0): higher in females (<0.01) and patients with dyslipidemia (<0.01), and increased according to the number of CV risk factors (considering hypertension, dyslipidemia and diabetes). Moreover, it significantly correlated with BNP, troponin at admission, ESR, C reactive protein-CRP, and fibrinogen. Cer(d18:1/24:1): significantly correlated with aging, BNP, fibrinogen and neutrophils. Cer(d18:1/16:0)/Cer(d18:1/24:0): higher in female patients (<0.05), and in patients with higher wall motion score index-WMSI (>1.7; ≤0.05), and in those with multivessel disease (<0.05). Moreover, it significantly correlated with aging, BNP, CRP, ESR, neutrophil-to-lymphocyte ratio-NRL, and fibrinogen. Cer(d18:1/18:0)/Cer(d18:1/24:0): higher in female patients (<0.001), and increased according to age. Moreover, it was higher in patients with lower left ventricular ejection fraction (<35%, ≤0.01), higher WMSI (>1.7, <0.05), and in those with multivessel disease (0.13 ± 0.06 vs. 0.10 ± 0.05 µM, <0.05), and correlates with BNP, ESR, CRP, fibrinogen and neutrophils, platelets, NLR, and troponin at admission. Multiple regression analysis showed that Cer(d18:1/16:0)/Cer(d18:1/24:0) and Cer(d18:1/18:0)/Cer(d18:1/24:0) remained as independent determinants for WMSI after multivariate adjustment (Std coeff 0.17, T-value 1.9, ≤0.05; 0.21, 2.6, <0.05, respectively). Conclusion: Distinct ceramide species are associated with CV risk, inflammation and disease severity in AMI. Thus, a detailed analysis of ceramides may help to better understand CV pathobiology and suggest these new biomarkers as possible risk predictors and pharmacological targets in AMI patients.

show abstract

“…Ceramide is a family of sphingomeric lipids composed of long chain bases of sphingosine and fatty acids heads. In the past few years, numerous studies have suggested that ceramides and other sphingolipids regulate cellular responses to extracellular stimuli and stress and they are involved in pathophysiological mechanism in many disease areas [3][4][5][6]. It has been proposed and confirmed by several researchers [7,8] that plasma ceramide level increased drastically in the presence of high level of LDL cholesterol.…”

Section: Introductionmentioning

confidence: 96%

Association between ceramides and coronary artery stenosis in patients with coronary artery disease

Xie

Wang

et al. 2020

Lipids Health Dis

View full text Add to dashboard Cite

Background: Coronary artery stenosis induces heart diseases including acute coronary syndrome (ACS). Some studies reported the ceramide species are associated with the ACS and major adverse cardia and cerebrovascular events (MACE). However, few studies investigated the association between plasma ceramide levels and the severity of stenosis, together with the onset of diseases. This aim of the present study was to investigate the association betweencertain ceramide species, coronary artery stenosis and acute coronary syndrome. Methods: Five hundred fifty-three patients with definite or suspected CAD were recruited and received angiography. Subjects were assigned into 4 groups according to the severity of coronary artery stenosis. The measurements of 4 plasma ceramide species, namely, Cer (d18:1/16:0), Cer (d18:1/18:0), Cer (d18:1/24:1), Cer (d18:1/24:0) were carried out by Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the ratio of Cer (d18:1/16:0), Cer (d18:1/18:0) and Cer (d18:1/24:1) to Cer (18:1/24:0), respectively, were calculated as index to evaluate the association between plasma ceramides levels and coronary artery stenosis. Multiple logistic regression analysis was used to establish the prognostic model for the prediction of ACS risk. Results: After the adjustment by multiple clinical risk factors including age, gender, pre-existing myocardial/ cerebral infarction, hemoglobin A1c% (HbA1c%), smoking and the diagnosis during index hospitalization, multiple logistic regression analysis showed that the high ratio of Cer (d18:1/24:1) to Cer (d18:1/24:0), female gender, HbA1c%, unstable angina (UAP) and acute myocardial infarction (AMI) diagnosis (compared with atherosclerosis) during index hospitalization were associated with more severe coronary artery stenosis. Furthermore, the prognostic model was established after adjustment of risk factors and the area under curve (AUC) of receiver operating characteristics (ROC) for the prognostic model was 0.732 and 95% CI was 0.642-0.822. Conclusion: The severity of coronary artery stenosis is associated with high ratio of Cer (d18:1/24:1) to Cer (d18:1/24:0), female gender, HbA1c% and AMI. Although the reported prognostic model showed a good discrimination, further investigation on long term MACE is needed to evaluate the role of ceramide for the prediction of MACE risk.

show abstract

Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes

Cited by 9 publications

References 14 publications

Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease

Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease

Ceramides and Cardiovascular Risk Factors, Inflammatory Parameters and Left Ventricular Function in AMI Patients

Association between ceramides and coronary artery stenosis in patients with coronary artery disease

Contact Info

Product

Resources

About